Yu. V. Fomicheva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu. V. Fomicheva has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Anna A. Kostareva
Almazov National Medical Research Centre
10 shared publications - Elena S. Vasichkina
Almazov National Medical Research Center
7 shared publications - O. V. Melnik
Almazov National Medical Research Center
5 shared publications - Tatiana L. Vershinina
Almazov National Medical Research Centre
5 shared publications - Tatiana M. Pervunina
Almazov National Medical Research Centre
4 shared publications - Artem Kiselev
Institute for Quantitative Health Science and Engineering (IQ), Michigan State University, East Lansing, MI, USA
3 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 487
Titin Serum Level Is Elevated in Patients with Myocarditis Depending on Their Genetic Background
Background: The molecular basis of myocarditis is often associated with genetic cardiomyopathies and truncating or loss-of-function variants in the titin gene (TTNtv/lof). Here, we hypothesize that titin serum levels increase in patients with myocarditis, and that this can depend on the genetic background of the disease. Methods: Forty-six patients with myocarditis were included in this study. Genotyping was performed using targeted panel sequencing. Serum titin levels and titin/creatinine ratios were measured in a subgroup of 27 patients. Results: Overall, 47 gene variants were identified, including 13 pathogenic and likely pathogenic variants and 34 variants of uncertain significance. The frequency of TTNtv/lof in patients with myocarditis was 11%. We detected significant differences between the TTNtv/lof group and the genotype-negative group in sustained ventricular tachycardia prevalence, myocardial reverse remodeling (∆ end-diastolic volume) and the prevalence of myocardial necrosis. Serum titin level was elevated in patients with myocarditis, negatively correlated with left ventricular ejection fraction, and was associated with ventricular arrhythmias and a low rate of myocardial reverse remodeling. Conclusions: In patients with biopsy-proven myocarditis, the rate of loss-of-function (LOF) variants was 28%, with a predominance of variants in structural and cytoskeletal genes, and TTNtv/lof variants were detected in 11% of patients. TTNtv/lof variant carriers were characterized by fewer morphological signs of inflammation and more favorable myocardial reverse remodeling. Serum titin levels were elevated in patients with myocarditis. Genotype-negative status of patients was characterized by the highest serum titin levels and titin/creatinine ratios, a lesser degree of myocardial reverse remodeling, sustained ventricular arrhythmias, and a larger area of necrosis.
- 28 September 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 487
Open AccessTitin Serum Level Is Elevated in Patients with Myocarditis Depending on Their Genetic Background
Background: The molecular basis of myocarditis is often associated with genetic cardiomyopathies and truncating or loss-of-function variants in the titin gene (TTNtv/lof). Here, we hypothesize that titin serum levels increase in patients with myocarditis, and that this can depend on the genetic background of the disease. Methods: Forty-six patients with myocarditis were included in this study. Genotyping was performed using targeted panel sequencing. Serum titin levels and titin/creatinine ratios were measured in a subgroup of 27 patients. Results: Overall, 47 gene variants were identified, including 13 pathogenic and likely pathogenic variants and 34 variants of uncertain significance. The frequency of TTNtv/lof in patients with myocarditis was 11%. We detected significant differences between the TTNtv/lof group and the genotype-negative group in sustained ventricular tachycardia prevalence, myocardial reverse remodeling (∆ end-diastolic volume) and the prevalence of myocardial necrosis. Serum titin level was elevated in patients with myocarditis, negatively correlated with left ventricular ejection fraction, and was associated with ventricular arrhythmias and a low rate of myocardial reverse remodeling. Conclusions: In patients with biopsy-proven myocarditis, the rate of loss-of-function (LOF) variants was 28%, with a predominance of variants in structural and cytoskeletal genes, and TTNtv/lof variants were detected in 11% of patients. TTNtv/lof variant carriers were characterized by fewer morphological signs of inflammation and more favorable myocardial reverse remodeling. Serum titin levels were elevated in patients with myocarditis. Genotype-negative status of patients was characterized by the highest serum titin levels and titin/creatinine ratios, a lesser degree of myocardial reverse remodeling, sustained ventricular arrhythmias, and a larger area of necrosis.
- Open Access
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4567
Potential and prospects for using biomedical resource collections obtained from pediatric patients for clinics and research
Aim . To demonstrate the development and potential applications of biomedical resource collections of pediatric patient biomaterials, as well as the potential for their differentiated use for clinical and research purposes in a multidisciplinary hospital setting at a federal research center. Material and methods . The study included biomaterial from pediatric patients and their first-degree relatives, banked between 2016 and 2025 as part of research projects at the Almazov National Medical Research Center in the field of clinical genetics and pediatrics. Deoxyribonucleic acid (DNA) isolated from whole blood samples and dried blood spots was used for genetic testing using modern molecular genetic diagnostic methods. Results . The potential of using bioresource collections of pediatric patient biomaterial was demonstrated using familial cases of rare monogenic diseases, for which previously collected biomaterial from the biobank was used to establish a diagnosis and determine follow-up strategies for family members, identify risks to future offspring, and receive advance data on the management of patients with specific hereditary syndromes. Additionally, the ability to predict new phenotypes associated with a known gene, and conversely, to uncover the relationship of new genes with a known phenotype, was demonstrated using examples of familial diseases, where biobank biomaterial enabled segregation analysis. Using biomaterial from cohorts of patients with a specific pathology, the potential for developing novel diagnostic algorithms and laboratory test systems, a differentiated approach to selecting a targeted genetic panel for diagnosis, and the identification of new clinical and genetic disease features was showed. A founder mutation was showed to be identified in a pathology determined in a specific ethnic group, with the potential to describe the onset time and geographic distribution. Conclusion . The creation of bioresource collections obtained from pediatric populations is a complex, yet extremely important, clinically necessary, and promising scientific task. Its implementation facilitates translational research aimed at improving diagnostic methods, understanding the pathogenesis and progression of childhood diseases, and the influence of environmental factors on their development. It also facilitates the search for new genetic causes of hereditary pathologies and the description of new phenotypes associated with known genes. It also identifies predictors of disease severity and prognosis. In the long term, it facilitates the search for novel therapeutic approaches and understanding the disease pathogenesis in adults.
- 23 January 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (11) , 4567
Open AccessPotential and prospects for using biomedical resource collections obtained from pediatric patients for clinics and research
Aim . To demonstrate the development and potential applications of biomedical resource collections of pediatric patient biomaterials, as well as the potential for their differentiated use for clinical and research purposes in a multidisciplinary hospital setting at a federal research center. Material and methods . The study included biomaterial from pediatric patients and their first-degree relatives, banked between 2016 and 2025 as part of research projects at the Almazov National Medical Research Center in the field of clinical genetics and pediatrics. Deoxyribonucleic acid (DNA) isolated from whole blood samples and dried blood spots was used for genetic testing using modern molecular genetic diagnostic methods. Results . The potential of using bioresource collections of pediatric patient biomaterial was demonstrated using familial cases of rare monogenic diseases, for which previously collected biomaterial from the biobank was used to establish a diagnosis and determine follow-up strategies for family members, identify risks to future offspring, and receive advance data on the management of patients with specific hereditary syndromes. Additionally, the ability to predict new phenotypes associated with a known gene, and conversely, to uncover the relationship of new genes with a known phenotype, was demonstrated using examples of familial diseases, where biobank biomaterial enabled segregation analysis. Using biomaterial from cohorts of patients with a specific pathology, the potential for developing novel diagnostic algorithms and laboratory test systems, a differentiated approach to selecting a targeted genetic panel for diagnosis, and the identification of new clinical and genetic disease features was showed. A founder mutation was showed to be identified in a pathology determined in a specific ethnic group, with the potential to describe the onset time and geographic distribution. Conclusion . The creation of bioresource collections obtained from pediatric populations is a complex, yet extremely important, clinically necessary, and promising scientific task. Its implementation facilitates translational research aimed at improving diagnostic methods, understanding the pathogenesis and progression of childhood diseases, and the influence of environmental factors on their development. It also facilitates the search for new genetic causes of hereditary pathologies and the description of new phenotypes associated with known genes. It also identifies predictors of disease severity and prognosis. In the long term, it facilitates the search for novel therapeutic approaches and understanding the disease pathogenesis in adults.
- 3 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 125-130
Phenotypic heterogeneity of Charcot–Marie–Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene
Charcot–Marie–Tooth disease belongs to the group of genetically and phenotypically heterogeneous sensory-motor polyneuropathies. Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal form of the disease caused by mutations in the mitofusin-2 gene (MFN2). More than 100 missense mutations in this gene have been registered to date. Many studies have demonstrated the variability of clinical presentation depending on the specific localization of the substitution. The presented clinical case shows the peculiarities of the phenotype of a patient with CMT2A disease associated with the c.1091G>C (p.Arg364Pro) missense mutation in the MFN2 gene.
- 3 June 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (5) , 125-130
Phenotypic heterogeneity of Charcot–Marie–Tooth type 2A disease associated with the c.1091G>C missense mutation (p.Arg364Pro) in the MFN2 gene
Charcot–Marie–Tooth disease belongs to the group of genetically and phenotypically heterogeneous sensory-motor polyneuropathies. Charcot–Marie–Tooth disease type 2A (CMT2A) is the most common axonal form of the disease caused by mutations in the mitofusin-2 gene (MFN2). More than 100 missense mutations in this gene have been registered to date. Many studies have demonstrated the variability of clinical presentation depending on the specific localization of the substitution. The presented clinical case shows the peculiarities of the phenotype of a patient with CMT2A disease associated with the c.1091G>C (p.Arg364Pro) missense mutation in the MFN2 gene.
- Open Access
- 7 May 2025
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 12 (1) , 6-14
Comparative informativeness of various targeted panels in the genetic diagnosis of hypertrophic cardiomyopathy in children
Introduction. Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy (CMP). Myocardial hypertrophy in children is associated with a large heterogeneous group of diseases with a high representation of non-sarcomeric causes. Purpose. The study compares diagnostic information from targeted next-generation sequencing (NGS) panels with different gene sets for HCM in children. Materials and methods. A molecular genetic study was conducted using two targeted panels (172 and 39 genes), followed by an assessment of their effectiveness. Results. The study included 53 children with HCM, the median age of which was 10 ± 3.5; 14.0 years. 13 children were examined using a large cardiac panel containing 172 genes. The remaining 40 patients were examined using a targeted panel for HCM containing 39 genes, while in 10 cases (25.0 %) genetic diagnostics was uninformative. Pathogenic and likely pathogenic variants in various genes were detected in 35 (66.0 %) patients. The informativeness of genetic diagnostics in the group of children under one year old was 60.7 %, in the group with onset at the age of over one year — 69.2 %. Conclusion. It is advisable to use an extended cardio panel for NGS for the purpose of genetic diagnosis of HCM in patients with the onset of the disease in the first year of life and small target panels for HCM in patients with the onset at an older age.
- 7 May 2025
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 12 (1) , 6-14
Open AccessComparative informativeness of various targeted panels in the genetic diagnosis of hypertrophic cardiomyopathy in children
Introduction. Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy (CMP). Myocardial hypertrophy in children is associated with a large heterogeneous group of diseases with a high representation of non-sarcomeric causes. Purpose. The study compares diagnostic information from targeted next-generation sequencing (NGS) panels with different gene sets for HCM in children. Materials and methods. A molecular genetic study was conducted using two targeted panels (172 and 39 genes), followed by an assessment of their effectiveness. Results. The study included 53 children with HCM, the median age of which was 10 ± 3.5; 14.0 years. 13 children were examined using a large cardiac panel containing 172 genes. The remaining 40 patients were examined using a targeted panel for HCM containing 39 genes, while in 10 cases (25.0 %) genetic diagnostics was uninformative. Pathogenic and likely pathogenic variants in various genes were detected in 35 (66.0 %) patients. The informativeness of genetic diagnostics in the group of children under one year old was 60.7 %, in the group with onset at the age of over one year — 69.2 %. Conclusion. It is advisable to use an extended cardio panel for NGS for the purpose of genetic diagnosis of HCM in patients with the onset of the disease in the first year of life and small target panels for HCM in patients with the onset at an older age.
- Open Access
- 17 July 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 226
The Role of NOTCH Pathway Genes in the Inherited Susceptibility to Aortic Stenosis
The NOTCH-signaling pathway is responsible for intercellular interactions and cell fate commitment. Recently, NOTCH pathway genes were demonstrated to play an important role in aortic valve development, leading to an increased calcified aortic valve disease (CAVD) later in life. Here, we further investigate the association between genetic variants in the NOTCH pathway genes and aortic stenosis in a case–control study of 90 CAVD cases and 4723 controls using target panel sequencing of full-length 20 genes from a NOTCH-related pathway (DVL2, DTX2, MFNG, NUMBL, LFNG, DVL1, DTX4, APH1A, DTX1, APH1B, NOTCH1, ADAM17, DVL3, NCSTN, DTX3L, ILK, RFNG, DTX3, NOTCH4, PSENEN). We identified a common intronic variant in NOTCH1, protecting against CAVD development (rs3812603), as well as several rare and unique new variants in NOTCH-pathway genes (DTX4, NOTCH1, DTX1, DVL2, NOTCH1, DTX3L, DVL3), with a prominent effect of the protein structure and function.
- 17 July 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (7) , 226
Open AccessThe Role of NOTCH Pathway Genes in the Inherited Susceptibility to Aortic Stenosis
The NOTCH-signaling pathway is responsible for intercellular interactions and cell fate commitment. Recently, NOTCH pathway genes were demonstrated to play an important role in aortic valve development, leading to an increased calcified aortic valve disease (CAVD) later in life. Here, we further investigate the association between genetic variants in the NOTCH pathway genes and aortic stenosis in a case–control study of 90 CAVD cases and 4723 controls using target panel sequencing of full-length 20 genes from a NOTCH-related pathway (DVL2, DTX2, MFNG, NUMBL, LFNG, DVL1, DTX4, APH1A, DTX1, APH1B, NOTCH1, ADAM17, DVL3, NCSTN, DTX3L, ILK, RFNG, DTX3, NOTCH4, PSENEN). We identified a common intronic variant in NOTCH1, protecting against CAVD development (rs3812603), as well as several rare and unique new variants in NOTCH-pathway genes (DTX4, NOTCH1, DTX1, DVL2, NOTCH1, DTX3L, DVL3), with a prominent effect of the protein structure and function.
- Open Access
- 21 July 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (10) , 4027
Left ventricular noncompaction associated with titin-truncating variants in the TTN gene
Aim. To study the association of genetic variants in the titin gene ( TTN ) with the development and clinical course of left ventricular noncompaction in different age groups. Material and methods. The article discusses three clinical cases of patients with left ventricular noncompaction who were treated at theAlmazovNationalMedicalResearchCenter. We performed a new-generation sequencing of 108 genes associated with cardiomyopathies, as well as whole exome sequencing and Sanger sequencing. Results. We identified genetic variants in the TTN gene leading to the synthesis of truncated protein: in the first two cases, the cause of noncompaction was a thirteen nucleotide deletion with a reading frame shift, in the second, a nonsense mutation. An algorithm for assessing the pathogenicity of the identified variants and a scheme of diagnostic genetic search are presented. Conclusion. Causal role of TTN -truncating variants in development of cardiomyopathies and, in particular, left ventricular noncompaction, requires a comprehensive clinical, segregation and bioinformatic analysis using international databases and the use of bioinformatics software.
- 21 July 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (10) , 4027
Open AccessLeft ventricular noncompaction associated with titin-truncating variants in the TTN gene
Aim. To study the association of genetic variants in the titin gene ( TTN ) with the development and clinical course of left ventricular noncompaction in different age groups. Material and methods. The article discusses three clinical cases of patients with left ventricular noncompaction who were treated at theAlmazovNationalMedicalResearchCenter. We performed a new-generation sequencing of 108 genes associated with cardiomyopathies, as well as whole exome sequencing and Sanger sequencing. Results. We identified genetic variants in the TTN gene leading to the synthesis of truncated protein: in the first two cases, the cause of noncompaction was a thirteen nucleotide deletion with a reading frame shift, in the second, a nonsense mutation. An algorithm for assessing the pathogenicity of the identified variants and a scheme of diagnostic genetic search are presented. Conclusion. Causal role of TTN -truncating variants in development of cardiomyopathies and, in particular, left ventricular noncompaction, requires a comprehensive clinical, segregation and bioinformatic analysis using international databases and the use of bioinformatics software.
- 15 June 2020
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 99 (3)
FEATURES OF THE CLINICAL PHENOTYPE OF FILAMINE CARDIOMYOPATHIES WITH A DEBUT IN EARLY CHILDHOOD
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- 15 June 2020
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 99 (3)
FEATURES OF THE CLINICAL PHENOTYPE OF FILAMINE CARDIOMYOPATHIES WITH A DEBUT IN EARLY CHILDHOOD
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.
- Open Access
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 92-99
Variants of RBM20 gene in pediatric patients with dilated cardiomyopathy
Варианты в гене RBM20 у пациентов детского возраста с дилатационной кардиомиопатией
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 92-99
Open AccessVariants of RBM20 gene in pediatric patients with dilated cardiomyopathy
Варианты в гене RBM20 у пациентов детского возраста с дилатационной кардиомиопатией
- Open Access
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 72-77-77
Clinical and diagnostic difficulties in management of patients with laminopathies
Клинико-диагностические сложности при ламинопатиях
- 3 November 2019
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 10,p. 72-77-77
Open AccessClinical and diagnostic difficulties in management of patients with laminopathies
Клинико-диагностические сложности при ламинопатиях
- Open Access
- 10 April 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 3,p. 54-59
BARTH SYNDROME IN PRACTICE OF CARDIOLOGY
СИНДРОМ БАРТА В ПРАКТИКЕ КАРДИОЛОГА
- 10 April 2018
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- No. 3,p. 54-59
Open AccessBARTH SYNDROME IN PRACTICE OF CARDIOLOGY
СИНДРОМ БАРТА В ПРАКТИКЕ КАРДИОЛОГА